The Most Effective, Efficient, and Clinically Proven Devices for Treating Nail Fungus and Acne

Medical-Grade Technology

FDA, ISO, CE, IEC cleared. Proven by exceptional clinical research (level 1 studies).

Quick & Convenient

Non-invasive 10 – 30 minute treatments with outstanding results.

Fast ROI

Make your investment back in months. We’ll help you at every stage.

Lunula Laser for Fungal Nail Treatment
Lunula® Laser: The only fully automated machine for treating nail fungus, and the only LLLT device to be FDA-cleared for fungal nail treatment.
EVRL® Laser: Handheld Device for Treating Acne and Pain Relief
EVRL® Laser: Cordless handheld device – only LLLT machine to be FDA-cleared for treating acne, and is efficacious for pain relief.

Erchonia’s non-thermal lasers are the only Low-Level Laser Therapy (LLLT) devices to be FDA Market Cleared for treating nail fungus (onychomycosis) and acne. The efficacy of our machines has been proven by multiple (level 1) double blind, randomised, placebo-controlled, and multi-site clinical studies – the most credible research in the market today. The treatments are short, effective, and easy to administer. There is no associated pain, reported side effects, or downtime, and the technology is safe with no health risks. We provide the training, ongoing support, and marketing, so you can focus on what matters most – your clients.

The Lunula Laser for Fungal Nail Treatment

Lunula®

Details …

Erchonia’s Lunula® Laser is the only LLLT device to be FDA Market Cleared for treating fungal nail infections.

Lunula® is easy to set up and use, and is the only automated system on the market today, allowing you to save on staff costs and increase profits.

The device targets onychomycosis through the use of two true laser beams (red 635nm and violet 405nm – monochromatic, collimated, and coherent), providing outstanding results in short 12 minute treatments.

The two wavelengths trigger a photochemical reaction, producing Reactive Oxygen Species which is converted to Hydrogen Peroxide – a natural antiseptic that kills onychomycosis. In addition, the red 635nm wavelength induces the production of Adenosine Triphosphate (ATP) which is converted to Nitric Oxide – aiding the natural immune response in fighting the infection.

> Download Data Sheet

EVRL acne laser treatment

EVRL®

Details …

The EVRL® Laser is a cordless handheld device with a simple graphic interface and preset / customisable protocols. It is the only LLLT device to be FDA Market Cleared for treating acne and bacterial, fungal, or viral infections, and is efficacious for pain management.

EVRL® utilises true laser technology, optimising photonic energy delivery through the use of monochromatic, collimated, and coherent beams of light. The device emits two true laser beams – a violet laser provides an antimicrobial effect through its 405nm line coherent beam (5mW output), and a red laser promotes healing through its 635nm line coherent beam (7.5mW output).

Used on its own or as an adjunct, EVRL® is effective for a wide variety of conditions, allowing you to expand your treatment range and grow your clinic.

> Download Data Sheet

Why Choose Erchonia®?

World Leaders in Medical-Grade Laser Therapy Technology

With over 25 years of experience, 16,000+ devices in the market, and 20 FDA-clearances, Erchonia® Corporation are world leaders in medical-grade Laser Therapy technology for medical / health professionals. Erchonia’s range of non-thermal, Low-Level Laser Therapy (LLLT) devices are used in many areas, including pain relief, fat removal, cellulite reduction, fungal nail treatment, and more. Based in the UK, Erchonia Lasers Ltd are a subsidiary organisation. We provide personal support to companies in Europe, Middle East, and Africa… Read More

91% Customer Satisfaction Rating

Our clients say it all: best products, service, training, and support.

Over 25 Years of Experience

Founded in 1996 – first Low-Level Laser in the world to gain FDA market clearance.

20 / 23 FDA-Clearances for Low-Level Lasers

Most credible research in the market – double blind, multi-site, randomised, placebo-controlled.

16,000+ Devices in the Market

Leaders in the field with over $5 million invested in R&D at any one time.

Ogi Bagatin (CEO, Bagatin Clinics)
Ken de Groot (DC, DABCO, DABDA)
Martin Andersen (DC, CCEP, MCC)